respiratory health

By Jonah Comstock January 10, 2019
Respiratory health company Propeller Health, which was recently acquired by ResMed for $225 million, announced this week in San Francisco a partnership with Walgreens and a new feature for users of its platform. The new feature, called My Pharmacy, will allow Propeller’s end users, patients with asthma and COPD, to connect to pharmacy services without leaving the Propeller app. At launch, users...
By Dave Muoio December 31, 2018
Jerusalem-based Teva Pharmaceuticals’ sensor-packed, app-connected digital inhaler has recently received marketing approval from the US FDA, according to a release from the company. The device will first become available next year through a “small number” of healthcare system pilot partnerships, with a full national launch currently planned for 2020. Teva’s ProAir Digihaler is indicated for the...
Adherium receives additional FDA clearance for OTC sale of inhaler sensors in the US

Credit: Adherium on Twitter

By Dave Muoio July 27, 2018
Connected inhaler sensor maker Adherium has received 510(k) clearance for US over-the-counter sales of its Hailie sensor, formerly known as Smartinhaler. Specifically, individual versions of the device have been cleared for use with the asthma inhalers ProAir HFA, Ventolin HFA, and Flovent HFA. “This latest clearance kicks off our official entry into the US consumer market, giving the tens of...
By Dave Muoio May 30, 2018
Today, Madison, Wisconsin-based digital respiratory health company Propeller Health announced a $20 million funding round led by a $10 million investment from Aptar Pharma. Existing investors Safeguard Scientifics, Social Capital, Hikma Ventures, 3M Ventures, and SR One comprised the other half of the round. According to a release, the new funding will be invested into the company’s digital...
By Jonah Comstock December 19, 2017
Brisbane, Australia-based ResApp is planning to re-do its big US trial soon, but in the meantime the smartphone respiratory diagnosis company is continuing to collect data in its native country. The company released data yesterday from a clinical study of more than 1,300 adult patients at Joondalup Health Campus in Perth and Wesley Hospital in Brisbane. While the company’s previous studies have...
By Jonah Comstock August 9, 2017
Brisbane, Australia-based digital health company ResApp has been talking up its Smartcough-C study — a multisite, double-blind study of the company’s smartphone-based respiratory analysis software — for a number of months. Conducted at Massachusetts General Hospital, Cleveland Clinic, and Texas Children’s Hospital, the trial was intended to support ResApp’s FDA submission for a number of...
By Jonah Comstock June 21, 2017
Madison, Wisconsin-based Propeller Health is now a decade old. The digital health company, which makes connected inhalers and patient- and provider-facing data analytics tools for respiratory diseases asthma and COPD, can hardly be considered a startup anymore. Nowadays the company has numerous published efficacy studies and business relationships with most major pharma companies in the...
By Jonah Comstock April 6, 2017
Two Minneapolis-based companies – digital health care management program maker HealthFactors and medical-focused R&D firm Koronis BioMedical Technologies (KBT) – are working together to create new smart inhaler products for some undisclosed pharmaceutical partners, the company announced earlier this week. “Connected health technology, including smart inhalers, has the ability to improve...
By Heather Mack December 12, 2016
Melbourne, Australia-based smart inhaler company Adherium has been selected to supply the technology for a multi-country research program in Europe that will seek to establish whether home monitoring and mobile health tools can be used to manage asthma. Adherium’s Smartinhaler technology, which uses sensors to track when medication is taken and then sends the data via Bluetooth to mobile devices...
By Aditi Pai April 20, 2016
Australia-based ResApp, a public company, has raised $9.74 million ($12.5 million Australian dollars) for its product, a smartphone-based system for diagnosing respiratory conditions. The company sold 62.5 million new ordinary shares at $0.16 ($0.20 AU) per share. ResApp’s offering essentially uses the smartphone microphone as a stethoscope to listen to a patient’s breathing. But instead of...

Editor's Pick